Dabrafenib plus trametinib - for the treatment of inoperable anaplastic thyroid cancer with the BRAF V600E variant dabrafenib plus trametinib for anaplastic thyroid cancer - All Wales Therapeutics and Toxicology CentreSkip to main contentOpens in new window * NHS Wales * NHS 111 Wales * Skip Navigation * Accessibility * Contact us * CymraegCymraeg * * All...Search All Wales Therapeutics and eventsShow Submenu For News, meetings and eventsNewsMeetingsEvents * About usShow Submenu For About usWho we areWhat we doOur committeesWho we work withOur researchOur reports and strategiesSustainabilityContact us More× * OW27 documents * NHS Wales * NHS 111 Wales * Accessibility * Contact us All...SearchPrint this page (expand headings to print hidden text)dabrafenib plus trametinib Status: Supported
Trametinib (Mekinist) Terms of use - Canada.ca * Skip to main content * Skip to "About government" Language selection * Français SearchSearch Canada.ca Search Topics menuMain Menu You are here: 1. Home 2. Health 3. Drug and health products 4. Licensing, authorizing and manufacturing drug and health products 5. Drug and health product review and approval 6. Clinical information on drugs and health
Trametinib - Mekinist Terms of use - Canada.ca * Skip to main content * Skip to "About government" Language selection * FrançaisSearchSearch Canada.ca Search Topics menuMain Menu You are here: 1. Home 2. Health 3. Drug and health products 4. Licensing, authorizing and manufacturing drug and health products 5. Drug and health product review and approval 6. Clinical information on drugs
Clinical commissioning policy: Trametinib in recurrent or progressive low grade serous ovarian cancer (adults) Skip to main contentCookies on the NHS England websiteWe’ve put some small files called cookies on your device to make our site work.We’d also like to use analytics cookies. These send information about how our site is used to a service called Google Analytics. We use this information to improve our site.Let us know if this is OK. We’ll use a cookie to save your choice. You can read more about our cookies before you choose. Change my preferences I'm OK with analytics cookiesHome News Publications Statistics Blogs Events Contact usSearch SearchAbout us Our work Commissioning Get involved CoronavirusClinical commissioning policy: Trametinib in recurrent or progressive low grade serous
Dabrafenib in combination with trametinib for treating BRAF V600 mutation-positive anaplastic thyroid cancer ACE Technology Guidances A Singapore Government Agency Website SEARCH Who We Are Organisational Structure Advisory Committees Committees We Serve Careers at ACE Healthcare Professionals ACE Clinical Guidances (ACGs) ACE CUES ACE Technology Guidances ACE Horizon Scanning Patients : * Dabrafenib 50 mg and 75 mg capsules in combination with trametinib 0.5 mg and 2 mg tablets for treating locally advanced or metastatic anaplastic thyroid cancer in patients with a BRAF V600 mutation and with no satisfactory locoregional treatment options
Clinical commissioning policy: Dabrafenib and trametinib in the treatment of patients with BRAF-mutated anaplastic thyroid cancer Skip to main contentHome News Publications Statistics Blogs Events Contact usSearch SearchAbout us Our work Commissioning Get involved CoronavirusClinical commissioning policy: Dabrafenib and trametinib in the treatment of patients with BRAF-mutated anaplastic thyroid cancerDocument first published:21 October 2022Page updated:21 October 2022Topic:Specialised commissioningPublication type:Policy or strategyThe combination of dabrafenib and trametinib is recommended to be available as a routine commissioning treatment option for anaplastic thyroid cancer (ATC) within the criteria set out in this document.DocumentClinical commissioning policy: Dabrafenib and trametinib
Dabrafenib (Tafinlar) and trametinib (Mekinist) combined, as adjuvant therapy for stage III melanoma with a BRAF V600 mutation Prescrire IN ENGLISH - Spotlight ''Dabrafenib (Tafinlar°) and trametinib (Mekinist°) combined, as adjuvant therapy for stage III melanoma with a BRAF V600 mutation'', 1 June 2020 {1}##LOC[OK]## {1} ##LOC[OK]## ##LOC[Cancel]## {1}##LOC[OK]####LOC[Cancel]## Register online International * Testimonials * Prescrire events * A global network Offers * Subscribe now * Solidarity Subscription Rate * Subscribers: register online * Prescrire's other products * Free Special Edition * Sign up to receive the newsletter english.prescrire.org > Spotlight > 100 most recent > Dabrafenib (Tafinlar°) and trametinib (Mekinist°) combined, as adjuvant therapy for stage III
Trametinib (Mekinist) - unresectable or metastatic melanoma with a BRAF V600 mutation. Published 8 March 2021 1 Product update SMC2328 trametinib 0.5mg, 2mg film-coated tablets (Mekinist®) Novartis Pharmaceuticals UK Ltd 5 February 2021 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and, following review by the SMC executive, advises NHS Boards and Area Drug and Therapeutics Committees (ADTCs) on its use in NHSScotland. The advice is summarised as follows: ADVICE: following an abbreviated submission trametinib (Mekinist®) is accepted for restricted use within NHSScotland. Indication under review: in combination with dabrafenib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation
Trametinib (melanoma) - Benefit assessment according to §35a Social Code Book V Extract 1 Translation of the executive summary of the dossier assessment Trametinib (Melanom)– Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 20 December 2018). Please note: This document was translated by an external translator and is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG Reports – Commission No. A18-60 Trametinib (melanoma) – Benefit assessment according to §35a Social Code Book V1 Extract of dossier assessment A18-60 Version 1.0 Trametinib (melanoma) 20 December 2018 Institute for Quality and Efficiency in Health Care (IQWiG
Final Results for Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma. The 5-year results of this trial showed that adjuvant therapy with dabrafenib plus trametinib resulted in longer relapse-free survival and distant metastasis-free survival than placebo among patients with V600-mutated stage III melanoma. Longer-term data were needed, including data regarding overall survival. We randomly assigned 870 patients with resected stage III melanoma with V600 mutations to receive 12 months of dabrafenib (150 mg twice daily) plus trametinib (2 mg once daily) or two matched placebos. Here, we report the final results of this trial, including results for overall survival, melanoma-specific survival, relapse-free survival, and distant metastasis-free survival. The median duration of follow
Targeting MXD1 sensitises pancreatic cancer to trametinib. The resistance of pancreatic ductal adenocarcinoma (PDAC) to trametinib therapy limits its clinical use. However, the molecular mechanisms underlying trametinib resistance in PDAC remain unclear. We aimed to illustrate the mechanisms of resistance to trametinib in PDAC and identify trametinib resistance-associated druggable targets, thus improving the treatment efficacy of trametinib-resistant PDAC. We established patient-derived xenograft (PDX) models and primary cell lines to conduct functional experiments. We also applied single-cell RNA sequencing, Assay for Transposase-accessible Chromatin with sequencing and Cleavage Under Targets and Tagmentation sequencing to explore the relevant molecular mechanism. We have identified a cancer
An 8-year-old girl with secondary histiocytic sarcoma with BRAF(V600) mutation following T-cell acute lymphoblastic leukemia demonstrating stable disease for 3 years on dabrafenib and trametinib - a case report and literature review. Histiocytic sarcoma as a secondary malignancy following childhood leukemia is extremely uncommon with fewer than 20 cases reported worldwide. They often pose was treated with MAPK-targeted therapy with dabrafenib and trametinib. She demonstrated excellent response and remained in partial remission with no signs of disease progression 3 years later. There is yet to be consensus on the optimal management for this neoplasm. Description of our successful clinical experience highlights that investigation for BRAF mutations in histiocytic sarcoma is potentially
Dabrafenib plus Trametinib in Pediatric Glioma with BRAF V600 Mutations. Detection of the V600E mutation in pediatric low-grade glioma has been associated with a lower response to standard chemotherapy. In previous trials, dabrafenib (both as monotherapy and in combination with trametinib) has shown efficacy in recurrent pediatric low-grade glioma with V600 mutations, findings that warrant further evaluation of this combination as first-line therapy. In this phase 2 trial, patients with pediatric low-grade glioma with V600 mutations who were scheduled to receive first-line therapy were randomly assigned in a 2:1 ratio to receive dabrafenib plus trametinib or standard chemotherapy (carboplatin plus vincristine). The primary outcome was the independently assessed overall response (complete
High throughput screening identifies dasatinib as synergistic with trametinib in low grade serous ovarian carcinoma. Low grade serous ovarian carcinoma (LGSOC) is a distinct histotype of ovarian cancer characterised high levels of intrinsic chemoresistance, highlighting the urgent need for new treatments. High throughput screening in clinically-informative cell-based models represents ) underwent synergy profiling with the recently approved MEK inhibitor trametinib. Disulfiram demonstrated excellent selectivity for LGSOC versus high grade serous ovarian carcinoma comparator lines (P = 0.003 for IC50 comparison), while the tyrosine kinase inhibitor dasatinib demonstrated favourable synergy with trametinib across multiple LGSOC models (maximum zero interaction potency synergy score 46.9
Dabrafenib and trametinib administration in patients with BRAF V600E/R or non-V600 BRAF mutated advanced solid tumours (BELIEVE, NCCH1901): a multicentre, open-label, and single-arm phase II trial. V600 mutations are common in melanoma, thyroid, and non-small-cell lung cancers. Despite dabrafenib and trametinib being standard treatments for certain cancers, their efficacy across various solid tumours remains unelucidated. The BELIEVE trial assessed the efficacy of dabrafenib and trametinib in solid tumours with V600E/R or non-V600 mutations. Between October 1, 2019, and June 2022, at least 50 patients with measurable and seven without measurable diseases examined were enrolled in a subcohort of the BELIEVE trial (NCCH1901, jRCTs031190104). mutated solid tumour cases other than V600E
Checkpoint Inhibition in Addition to Dabrafenib/Trametinib for BRAF(V600E) Mutated Anaplastic Thyroid Carcinoma. The dabrafenib plus trametinib combination (DT) has revolutionized treatment of BRAFV600E-mutated anaplastic thyroid carcinoma (BRAFm-ATC). However, patients eventually develop resistance and progress. Single-agent anti-PD-1 inhibitor spartalizumab has shown a median overall survival group, where mOS was the longest (63.0 months [95%CI,15.5-110.5]). No grade 5 adverse events (AEs) occurred in all three cohorts, and 32.4% had immune-related AEs, most frequently hepatitis and colitis. Our results show that in BRAFm-ATC, addition of pembrolizumab to dabrafenib/trametinib may significantly prolong survival. Surgical resection of the primary tumor after initial BRAF-targeted therapy